% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pouyiourou:176959,
      author       = {M. Pouyiourou$^*$ and T. Wohlfromm$^*$ and B. Kraft$^*$ and
                      T. Hielscher$^*$ and D. Stichel and A. von Deimling and S.
                      Delorme$^*$ and V. Endris and O. Neumann and A. Stenzinger
                      and A. Krämer$^*$ and T. Bochtler$^*$},
      title        = {{L}ocal ablative treatment with surgery and/or radiotherapy
                      in single-site and oligometastatic carcinoma of unknown
                      primary.},
      journal      = {European journal of cancer},
      volume       = {157},
      issn         = {0959-8049},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2021-02192},
      pages        = {179 - 189},
      year         = {2021},
      note         = {#EA:A360#LA:A360#},
      abstract     = {Single-site carcinoma of unknown primary (CUP) is
                      recognised as a distinct favourable subtype in the European
                      Society of Medical Oncology (ESMO) classification. There is
                      broad consensus that these patients are candidates for local
                      ablative treatment strategies with surgery and/or
                      radiotherapy, but data on their outcomes are scarce.In this
                      study, we have addressed the prospects of cure and
                      prognostic factors in a retrospective cohort of 63 patients
                      who were eligible for local treatment at our centre.Median
                      event-free (EFS) and overall survival (OS) were 15.6 months
                      and 52.5 months, respectively. Of 61 patients who received
                      local treatment, 20 $(32.8\%)$ remained event-free over a
                      median follow-up of 28 months. Baseline clinical parameters
                      including affected organ, number, volume and histology of
                      metastases had no significant impact on prognosis, whereas
                      deleterious TP53 mutations and DNA copy number loss
                      emerged as independent adverse risk factors with respect to
                      EFS. Surgical treatment was associated with improved OS as
                      compared to radiation-based therapy.Our study advocates to
                      pursue localised treatment with surgery and/or radiotherapy
                      whenever feasible and implies that genetic parameters might
                      additionally determine the clinical course of single-site
                      CUP patients.},
      keywords     = {CUP (cancer of unknown primary) (Other) / Copy number loss
                      (Other) / Oligometastasis (Other) / Prognosis (Other) /
                      Radiotherapy (Other) / Single metastatic deposit (Other) /
                      Surgery (Other) / TP53 (Other)},
      cin          = {A360 / C060 / E010},
      ddc          = {610},
      cid          = {I:(DE-He78)A360-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)E010-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34521064},
      doi          = {10.1016/j.ejca.2021.08.019},
      url          = {https://inrepo02.dkfz.de/record/176959},
}